WO2013078658A1 - Morus berries and avoiding glucose peaks - Google Patents
Morus berries and avoiding glucose peaks Download PDFInfo
- Publication number
- WO2013078658A1 WO2013078658A1 PCT/CN2011/083299 CN2011083299W WO2013078658A1 WO 2013078658 A1 WO2013078658 A1 WO 2013078658A1 CN 2011083299 W CN2011083299 W CN 2011083299W WO 2013078658 A1 WO2013078658 A1 WO 2013078658A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- morus
- accordance
- mulberry
- berries
- Prior art date
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 52
- 239000008103 glucose Substances 0.000 title claims abstract description 52
- 241000218213 Morus <angiosperm> Species 0.000 title claims abstract description 31
- 235000021028 berry Nutrition 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 53
- 235000013305 food Nutrition 0.000 claims abstract description 42
- 239000008280 blood Substances 0.000 claims abstract description 38
- 210000004369 blood Anatomy 0.000 claims abstract description 38
- 230000002641 glycemic effect Effects 0.000 claims abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 230000002265 prevention Effects 0.000 claims abstract description 4
- 240000000249 Morus alba Species 0.000 claims description 46
- 235000008708 Morus alba Nutrition 0.000 claims description 46
- 150000001720 carbohydrates Chemical class 0.000 claims description 25
- 235000014633 carbohydrates Nutrition 0.000 claims description 25
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 18
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 claims description 16
- 235000012054 meals Nutrition 0.000 claims description 14
- 206010012601 diabetes mellitus Diseases 0.000 claims description 13
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 10
- 208000008589 Obesity Diseases 0.000 claims description 10
- 235000020824 obesity Nutrition 0.000 claims description 10
- 102000004877 Insulin Human genes 0.000 claims description 9
- 108090001061 Insulin Proteins 0.000 claims description 9
- 229940125396 insulin Drugs 0.000 claims description 9
- 235000013361 beverage Nutrition 0.000 claims description 8
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 8
- 206010056997 Impaired fasting glucose Diseases 0.000 claims description 7
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 235000006723 Morus australis Nutrition 0.000 claims description 4
- 240000009253 Morus australis Species 0.000 claims description 4
- 244000278455 Morus laevigata Species 0.000 claims description 4
- 235000013382 Morus laevigata Nutrition 0.000 claims description 4
- 206010033307 Overweight Diseases 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 229930002877 anthocyanin Natural products 0.000 claims description 3
- 235000010208 anthocyanin Nutrition 0.000 claims description 3
- 239000004410 anthocyanin Substances 0.000 claims description 3
- 150000004636 anthocyanins Chemical class 0.000 claims description 3
- 229930003935 flavonoid Natural products 0.000 claims description 3
- 150000002215 flavonoids Chemical class 0.000 claims description 3
- 235000017173 flavonoids Nutrition 0.000 claims description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 230000005856 abnormality Effects 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 230000037221 weight management Effects 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 229930014626 natural product Natural products 0.000 abstract description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 18
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 239000000047 product Substances 0.000 description 14
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 12
- 235000013339 cereals Nutrition 0.000 description 11
- 230000000291 postprandial effect Effects 0.000 description 11
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 230000037406 food intake Effects 0.000 description 9
- 235000021559 Fruit Juice Concentrate Nutrition 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 6
- 235000012794 white bread Nutrition 0.000 description 6
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229960002632 acarbose Drugs 0.000 description 5
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 235000015203 fruit juice Nutrition 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000000378 dietary effect Effects 0.000 description 4
- 235000021579 juice concentrates Nutrition 0.000 description 4
- 230000036186 satiety Effects 0.000 description 4
- 235000019627 satiety Nutrition 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000014101 glucose homeostasis Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000001497 healthy food Nutrition 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 238000007427 paired t-test Methods 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229940123208 Biguanide Drugs 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000021024 carbohydrate-rich diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000012182 cereal bars Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011217 control strategy Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000004121 glycogenesis Effects 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011542 limb amputation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates generally to the field of food products.
- the present invention aims at natural compounds that can help to reduce glucose peaks in the blood of a subject after consumption of food with a high glycemic index.
- One embodiment of the present invention is a composition comprising an extract of the berries of Morus spp. for use in the treatment or prevention of disorders linked to foods with a high glycemic index.
- Obesity develops when energy intake is greater than energy expenditure, the excess energy being stored mainly as fat in adipose tissue. Obesity is often caused by the consumption of food products with a high caloric density, with most of the calories coming from easily digestible carbohydrates.
- Food products with more complex carbohydrates that take longer to digest may be used to increase the duration of satiety and to minimize the risk of developing obesity.
- Food products with easily digestible carbohydrates are generally more liked and hence preferred by the consumer.
- Obesity represents a serious threat to health because it is associated with an array of chronic diseases, including, e.g., diabetes .
- Diabetes mellitus is a metabolic condition characterized primarily by high blood glucose levels that result from the body's inability to make or use insulin. Hyperglycemia can lead to numerous clinical complications including blindness, limb amputations, heart attack or stroke. In 2007, it was estimated that 246 million of adults have diabetes, and if nothing is done to slow down the epidemic, within 25 years the number will reach more than 380 million.
- Type-1 diabetes T1D
- type-2 diabetes T2D
- T1D insulin-dependent diabetes
- T2D type-2 diabetes
- the increase in type-2 diabetes is mainly driven by increasing obesity rates.
- IGT impaired glucose tolerance
- IFG impaired fasting glucose
- the oral glucose tolerance test may be performed to assess whether the patient is diabetic or has IGT.
- the OGTT consists of a glucose drink containing 75g of glucose. The patient's blood sugar level is measured at one and two hours following administration of the drink. As glucose is an essential nutrient for the human body, its circulating levels must be carefully maintained constant, in order to supply adequate amounts to peripheral tissues.
- the liver plays a central role in glucose homeostasis by balancing its uptake and storage via glycogenesis and its release via glycogenolysis and gluconeogenesis . An impairment of glucose homeostasis is a typical feature of T2D.
- HGP hepatic glucose production
- T2D Total ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇
- Mulberry leaves have been used in Chinese Medicine to cure and prevent 'Xiao-ke' (diabetes) .
- using leaves has the disadvantage that they are subject to environmental circumstances for a very long time and, hence, may contain pesticides or other unwanted compounds.
- the present inventors have found that the addition of mulberry fruit concentrate and/or juice to starch, sucrose and/or maltose rich foods and beverages can reduce the speed of glucose generation in the gut, and therefore contribute to a slow release of glucose into the blood, resulting in a low glycemic response and prolonged availability of sugar as energy source.
- mulberry fruit concentrate and/or juice to food products with a high carbon content allows making available increased glucose levels in the blood later on, in particular 2-4 hours after ingestion, for example 2.5 - 4 hours after ingestion.
- the present invention allows using the generally well liked easily digestible carbohydrates in food products while having the advantage that these carbohydrates are in fact slowly digested. Hence, a similar effect is achieved as if one was using more complex carbohydrates, while taste issues are avoided.
- Standardized fruit extracts may be used directly, as concentrates or in powdered form for applications in food and beverage products, supplements or pharmaceutical preparations for healthcare and adult nutrition.
- compositions provide naturally produced, cost-effective components that have a demonstrated hypoglycemic and long- lasting energy effect in carbohydrate rich foods (e.g., porridge, pasta, cereal bars, cereal drinks, biscuits) , and sucrose and/or maltose rich beverages and foods (e.g., ice cream) .
- carbohydrate rich foods e.g., porridge, pasta, cereal bars, cereal drinks, biscuits
- sucrose and/or maltose rich beverages and foods e.g., ice cream
- one embodiment of the present invention is a composition comprising an extract of the berries of Morus spp. for use in the treatment or prevention of conditions linked to foods with a high glycemic index.
- the composition may be a food composition with a high glycemic index to which an extract of the berries of Morus spp. was added . Consequently, the composition may further comprise a carbohydrate source.
- the carbohydrate source may represent at least 50 %, preferably at least 65 %, more preferred at least 80 % of the energy of the composition.
- the composition may have an energy density in the range of about 0.2 kcal/g to 5 kcal/g.
- a further embodiment of the present invention is a composition comprising an extract of the berries of Morus spp . for reducing glucose peaks and/or insulin peaks after ingestion of a food product, while ensuring a long term provision of energy
- composition of the present invention may be used to increase the energy that can be made available from an ingested product 2-4 hours after ingestion.
- This use may be medical or non-medical.
- the glycemic index is a measure of the effects of carbohydrates on blood sugar levels. Carbohydrates that break down quickly during digestion and release glucose rapidly into the bloodstream have a high GI; carbohydrates that break down more slowly, releasing glucose more gradually into the bloodstream, have a low GI .
- the glycemic index of a food is defined as the area under the two hour blood glucose response curve (AUC) following the ingestion of a fixed portion of carbohydrate (usually 50 g) .
- the AUC of the test food is divided by the AUC of the standard (glucose) and multiplied by 100. Glucose has hence a GI of 100 per definition.
- Food compositions with a GI of > 70 shall be understood as food composition with a high glycemic index.
- food compositions with a high glycemic index may have a GI of above 75, above 80, above 85, above 90, or above 95.
- the extract of the berries of Morus spp . may be any preparation of berries of Morus spp., e.g., juice or a dried fruit extract.
- Berries of Morus spp. have for example the advantage that the plant can be reused annually. Furthermore, berries of Morus spp. are generally well liked and have no negative influence on the taste of a product. Berries of Morus spp. are also well accepted as consumable product. Even further, the berries of Morus spp. naturally contain citric acid which is toxic for unwanted micro-organisms.
- the extract of the berries of Morus spp. shows in particular beneficial effects if it is directly co-administered with the food product with the high glycemic index.
- composition of the present invention serves to treat or prevent conditions and/or disorders, for example chronic diseases, linked to foods with a high glycemic index. It avoids the generation of glucose peaks in the bloodstream. As such, the composition of the present invention may be used to at least partially avoid the generation of glucose peaks in the blood of a consumer after consumption of a meal or beverage rich in digestible carbohydrates.
- the meal may be a food rich in digestible carbohydrates, and the beverage may be rich in sucrose and/or maltose. It allows increasing the time span during which a body can use ingested food as energy source. Hence, the composition of the present invention may be used to increase the time span during which energy can be extracted from ingested food.
- the disorders linked to foods with a high glycemic index may be selected from the group consisting of glucose intolerance abnormalities, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), diabetes, overweightness , obesity, high blood pressure, high blood cholesterol, and heart disease.
- ITT impaired glucose tolerance
- IGF impaired fasting glucose
- Weight is defined for an adult human as having a BMI between 24 and 28 in China or 25 and 30 in western countries.
- Body mass index or “BMI” means the ratio of weight in kg divided by the height in metres, squared.
- “Obesity” is a condition in which the natural energy reserve, stored in the fatty tissue of animals, in particular humans and other mammals, is increased to a point where it is associated with certain health conditions or increased mortality. "Obese” is defined for an adult human as having a BMI greater than 28 in China and 30 in western countries. The composition may also be used to support weight management.
- composition of the present invention may also consist of an extract of the berries of Morus spp .
- the composition of the present invention may be any kind of consumable composition, for example selected from the group consisting of food products, animal food products or pharmaceutical compositions.
- the composition may be a nutritional composition, a nutraceutical , a drink, a food additive or a medicament.
- composition of the present invention may be intended to be consumed immediately before, during and/or immediately after a meal or beverage.
- time frame ranging form about 30 minutes before a meal to about 30 minutes after a meal, preferably about 15 minutes before a meal to about 15 minutes after a meal.
- composition is to be consumed during a meal, it may be intended to be mixed with the meal or it may be consumed as accompanying drink, for example.
- the Morus spp. may be selected from the group consisting of White Mulberry (Morus alba L.) , Black Mulberry (Morus nigra L.), American Mulberry, Red Mulberry (Morus rubra L.) , hybrid forms between Morus alba and Morus rubra, Korean Mulberry (Morus australis) , Himalayan Mulberry (Morus laevigata) , and combinations thereof
- composition of the present invention may contain any amount of an extract of the berries of Morus spp..
- the effectiveness of the composition follows a dose-response curve which eventually reach a plateau phase at very high concentrations of an extract of the berries of Morus spp ..
- the composition of the present invention may comprise at least 10 weight-%, at least 20 weight-%, at least 30 weight-%, at least 40 weight-%, at least 50 weight-%, at least 60 weight-%, at least 70 weight-%, at least 80 weight-%, or at least 90 weight-% of an extract of the berries of Morus spp .
- the berries of Morus spp. contain for example 1- deoxyno j irimycin (DNJ) in very large quantities compared to other plants and other parts of the Morus plant.
- DNJ 1- deoxyno j irimycin
- 1-deoxyno jirimycin is thought to inhibit intestinal and pancreatic a-glucosidase.
- the composition comprises at least 0.1 mg 1-deoxyno jirimycin (DNJ) per g dry weight, preferably at least 1 mg DNJ per g dry weight.
- the berries of Morus ssp. contain also anthocyanins and flavonoids, which both have beneficial effects for the health of the consumer.
- composition of the present invention may comprise DNJ, anthocyanins and flavonoids in a weight ratio in the range of about 1:0.07:0.05 to 1:45:1.5.
- DNJ may act in concert and/or synergistically with other analogues of DNJ present in mulberry.
- the present invention also extends to a method to reduce the glycemic index of a food product, e.g. a food product with a high glycemic index, comprising the step of adding an extract of the berries of Morus spp . to the food product.
- Figure 1 shows the blood glucose response of maltose in mice as affected by mulberry fruit juice (MB) at different dose levels or the positive control acarbose. Data are average of results from 10 mice. Detailed description can be found in Example 1 below.
- MB mulberry fruit juice
- Figure 2 shows postprandial blood glucose response of white bread as affected by MB in healthy subjects. Detailed description can be found in the Example 2 below.
- Figure 3 shows the effect of mulberry juice on blood glucose level in Chinese adults.
- mice age around 5 weeks old and body weight around 24-28 g were purchased from Shanghai Slac Laboratory Animal Co Ltd. They were hosted in a SPF grade animal facility and maintained under 12:12 light-dark cycle with free access to water and food.
- the regular diet contained 24% protein, 5.4% fat and 59% carbohydrate by weight.
- Mulberry fruit juice (MB) to be tested was in a concentrated form ( 60 0 Brix) and obtained from the Bosun Healthy Food R&D Center Guangdong, China. It was dissolved in distilled water to the final concentration of 0.1, 0.2 and 0.4 g/ml. Maltose was dissolved in distilled water to a final concentration of 0.25 g/ml. Acarbose was dissolved in distilled water to a final concentration of 2 mg/ml.
- the dietary treatment of five groups were as following:
- mice in group 1 to 3 were given 10 ml/kg of maltose (0.25 g/ml) together with 10 ml/kg of different doses of MB (0.1, 0.2 and 0.4 g/ml) by gavage .
- the mice in group 4 were given 10 ml/kg of maltose (0.25g/ml) together with 10 ml/kg of acarbose (2mg/ml) by gavage .
- the mice in group 5 were given 10 ml/kg of maltose
- Example 2 A crossover clinical study was designed to study the postprandial glycemia after ingestion of mulberry fruit juice (MB) with a high carbohydrate diet (white bread) .
- MB mulberry fruit juice
- white bread a high carbohydrate diet
- Control Product White bread plus 10 g of a sugar solution containing same amount of mono- and di-sugars as in 10 g of MB. And the total digestible carbohydrates are 75 grams.
- Test Product White bread plus 10 g of MB with total of 75 grams of digestible carbohydrates.
- White Bread was purchased from Walmart (Zhichun Road Store) in Beijing.
- Mulberry fruit juice concentrate was 60 0 Brix, obtained from Bosun Healthy Food R&D Center Guangdong, China.
- Sugar solution was prepared by Nestle R&D Shanghai based on the results of component analysis of mulberry juice.
- Subjects Twenty-three healthy subjects participated in this study. The age of subjects ranged from 20 to 50 year old, 16 females and 7 males. The average Body Mass Index (BMI) was 21.54 kg/m 2 , ranging from 18.08 - 24.44.
- BMI Body Mass Index
- mice were randomly given either control product or test product after overnight fasting. The washout period was one week. All dietary products were taken orally. All foods were consumed within 12 minutes, 250 ml of water was given with each product. A stopwatch was started for each subject as soon as the subject started eating. Blood samples were collected at time 0, 15, 30, 45, 60, 90, and 120 minutes for postprandial glucose monitoring.
- the incremental blood glucose AUC was determined by a mixed log-linear trapezoidal model, excluding area that fell below 0 min values.
- the mixed log-linear trapezoidal model performed the AUC calculation in the following way: the linear rule (trapezoidal) is applied to the range where concentration is ascending and the log linear rule is applied to the range where concentration is descending. Combination of the two trapezoidal methods enhance the estimation of the AUC in reducing errors inherent to both methods by applying them under condition of best estimate.
- Example 3 The effect of mulberry juice on blood glucose level in Chinese adults was assessed.
- This clinical trial demonstrates the effect of mulberry juice concentrate on long-lasting energy, especially the Tmax and Cmax of 4-hour postprandial blood glucose after taking the mulberry juice together with a cereal.
- the primary parameters were the changes in blood glucose level after co-ingesting mulberry juice with a rice-based cereal with a high carbohydrate content as comparing to the cereal alone.
- the clinical trial also allows showing the effect of mulberry juice on the time it takes the blood glucose level to return to baseline level.
- the subjects were tested on two dietary treatments in a random order, while the washout period was 1 week.
- Treatment 1 Rice-based cereal flakes plus sugar solution containing same amount of mono- and di-sugars as in mulberry fruit juice concentrate.
- Treatment 2 Rice-based cereal flakes plus mulberry fruit juice concentrate.
- Mulberry fruit juice concentrate Brix 60 (approx. 60% sugar), was obtained from Bosun Healthy Food R&D Center of Guangdong, China . lOg of Mulberry fruit juice concentrate or lOg of sugar solution were consumed together with the cereal. Total food portion (cereal with sugar solution or cereal with mulberry fruit juice) contained 75 g digestible carbohydrates.
- the experimental period was 8 ⁇ 1 days.
- each subject received one of the two treatments in a random manner after an overnight fast, and consumed the treatment within 12 minutes.
- Venous blood samples were drawn immediately before eating and at 15, 30, 45, 60, 90, 120, 150, 180, 210, and 240 min after eating has commenced.
- each subject received another one of the two treatments in an identical fashion, venous blood samples were drawn in an identical fashion. The total duration for each subject was around two weeks.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Obesity (AREA)
- Botany (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A composition comprising an extract of the berries of Morus spp.for use in the treatment or prevention of disorders linked to foods with a high glycemic index.The extract of the berries of Morus spp. may also be provided as natural compounds that can help to reduce glucose peaks in the blood of a subject after consumption of food with a high glycemic index.
Description
Morus berries and avoiding glucose peaks Technical Field
The present invention relates generally to the field of food products. For example, the present invention aims at natural compounds that can help to reduce glucose peaks in the blood of a subject after consumption of food with a high glycemic index. One embodiment of the present invention is a composition comprising an extract of the berries of Morus spp. for use in the treatment or prevention of disorders linked to foods with a high glycemic index.
Background Art
During the past decades, the prevalence of obesity has increased worldwide to epidemic proportion. Approximately 1 billion of people worldwide are overweight or obese, conditions that increase mortality, mobility and economical costs .
Obesity develops when energy intake is greater than energy expenditure, the excess energy being stored mainly as fat in adipose tissue. Obesity is often caused by the consumption of food products with a high caloric density, with most of the calories coming from easily digestible carbohydrates.
Food products with more complex carbohydrates that take longer to digest may be used to increase the duration of satiety and to minimize the risk of developing obesity. Unfortunately, however, food products with easily digestible carbohydrates are generally more liked and hence preferred by the consumer.
Obesity represents a serious threat to health because it is associated with an array of chronic diseases, including, e.g., diabetes .
Diabetes mellitus is a metabolic condition characterized primarily by high blood glucose levels that result from the body's inability to make or use insulin. Hyperglycemia can lead to numerous clinical complications including blindness, limb amputations, heart attack or stroke. In 2007, it was estimated that 246 million of adults have diabetes, and if nothing is done to slow down the epidemic, within 25 years the number will reach more than 380 million.
The most common types of diabetes are insulin-dependent diabetes (Type-1 diabetes, T1D) and type-2 diabetes (T2D) , which is by far the most abundant type. The increase in type-2 diabetes is mainly driven by increasing obesity rates. Today, more than 1.1 billion people are estimated to be overweight, of which around 320 million are obese.
The pathophysiology of the development of T2D is complex and multifactorial. Obesity, sedentary life style and/or increased age may lead to insulin resistance and to increased circulating insulin concentrations over time. At some point a loss of control of blood glucose begins to emerge, resulting in impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) and may ultimately result in T2D. Therefore IGT and IFG refer to metabolic states intermediate between normal glucose homeostasis and diabetes.
A further test, the oral glucose tolerance test (OGTT) , may be performed to assess whether the patient is diabetic or has IGT. The OGTT consists of a glucose drink containing 75g of glucose. The patient's blood sugar level is measured at one and two hours following administration of the drink.
As glucose is an essential nutrient for the human body, its circulating levels must be carefully maintained constant, in order to supply adequate amounts to peripheral tissues. The liver plays a central role in glucose homeostasis by balancing its uptake and storage via glycogenesis and its release via glycogenolysis and gluconeogenesis . An impairment of glucose homeostasis is a typical feature of T2D. Patients with T2D exhibit increased hepatic glucose production (HGP) , which is identified as the main cause of fasting hyperglycaemia and is associated with a reduced plasma glucose clearance (Gastaldelli A, et al . , Diabetes 2000; 49:1367-1373 ), and a 25-45% reduced synthesis of glycogen compared with non- diabetic subjects (Roden M, et al . , Best Pract Res Clin Endocrinol Metab. 2003;17:365-83). Limiting blood glucose peaks after a meal, in particular in diabetic subjects, constitutes an important target of the overall glycemic control strategy.
Actual treatments for T2D comprise several classes of drugs, which can be used alone or in combination with insulin. Biguanides work by reducing the amount of glucose produced by the liver. Obese patients with T2D are usually started on biguanides. Common side effects include abdominal discomfort, diarrhea, nausea or vomiting, loss of appetite, and metallic taste . Alpha-glucosidase inhibitors slow the digestion of carbohydrates, delay glucose absorption, and reduce the increase in blood glucose after a meal. Common side effects include abdominal pain, diarrhea, and flatulence.
However, it would be desirable to have available a natural compound which is safe to administer without unwanted side
effects and that can be used to keep blood glucose levels under control.
Mulberry leaves have been used in Chinese Medicine to cure and prevent 'Xiao-ke' (diabetes) . However, using leaves has the disadvantage that they are subject to environmental circumstances for a very long time and, hence, may contain pesticides or other unwanted compounds.
Contents of the Invention
Hence, it was the object of the present invention to provide the art with a natural and water miscible, ideally water soluble, composition that is safe to administer without side effects and without the need for consultation of medical personnel and that can be used to avoid or reduce glucose peaks after consumption of food with a high glycemic index.
The present inventors have addressed this need and were surprised to see that they could achieve this object by the subject matter of the independent claims. The dependant claims further develop the idea of the present invention.
In particular, the present inventors have found that the addition of mulberry fruit concentrate and/or juice to starch, sucrose and/or maltose rich foods and beverages can reduce the speed of glucose generation in the gut, and therefore contribute to a slow release of glucose into the blood, resulting in a low glycemic response and prolonged availability of sugar as energy source.
It was found for example, that the addition of mulberry fruit concentrate and/or juice to food products with a high carbon content allows making available increased glucose levels in
the blood later on, in particular 2-4 hours after ingestion, for example 2.5 - 4 hours after ingestion.
Without wishing to be bound by theory, the inventors presently believe that this effect is achieved via the inhibition of alpha-glucosidase by an extract of the berries of Morus spp ..
Hence, the present invention allows using the generally well liked easily digestible carbohydrates in food products while having the advantage that these carbohydrates are in fact slowly digested. Hence, a similar effect is achieved as if one was using more complex carbohydrates, while taste issues are avoided.
Standardized fruit extracts may be used directly, as concentrates or in powdered form for applications in food and beverage products, supplements or pharmaceutical preparations for healthcare and adult nutrition.
These preparations provide naturally produced, cost-effective components that have a demonstrated hypoglycemic and long- lasting energy effect in carbohydrate rich foods (e.g., porridge, pasta, cereal bars, cereal drinks, biscuits) , and sucrose and/or maltose rich beverages and foods (e.g., ice cream) .
Hence, one embodiment of the present invention is a composition comprising an extract of the berries of Morus spp. for use in the treatment or prevention of conditions linked to foods with a high glycemic index.
The composition may be a food composition with a high glycemic index to which an extract of the berries of Morus spp. was added .
Consequently, the composition may further comprise a carbohydrate source.
The carbohydrate source may represent at least 50 %, preferably at least 65 %, more preferred at least 80 % of the energy of the composition.
The composition may have an energy density in the range of about 0.2 kcal/g to 5 kcal/g.
A further embodiment of the present invention is a composition comprising an extract of the berries of Morus spp . for reducing glucose peaks and/or insulin peaks after ingestion of a food product, while ensuring a long term provision of energy
The inventors were able to demonstrate in clinical studies that the composition of the present invention also produced a significant reduction in insulin response. The composition of the present invention may be used to increase the energy that can be made available from an ingested product 2-4 hours after ingestion.
This use may be medical or non-medical.
The glycemic index (GI) is a measure of the effects of carbohydrates on blood sugar levels. Carbohydrates that break down quickly during digestion and release glucose rapidly into the bloodstream have a high GI; carbohydrates that break down more slowly, releasing glucose more gradually into the bloodstream, have a low GI . The glycemic index of a food is defined as the area under the two hour blood glucose response curve (AUC) following the ingestion of a fixed portion of carbohydrate (usually 50 g) .
The AUC of the test food is divided by the AUC of the standard (glucose) and multiplied by 100. Glucose has hence a GI of 100 per definition.
Food compositions with a GI of > 70 shall be understood as food composition with a high glycemic index.
For example, food compositions with a high glycemic index may have a GI of above 75, above 80, above 85, above 90, or above 95.
The extract of the berries of Morus spp . may be any preparation of berries of Morus spp., e.g., juice or a dried fruit extract.
Berries of Morus spp. have for example the advantage that the plant can be reused annually. Furthermore, berries of Morus spp. are generally well liked and have no negative influence on the taste of a product. Berries of Morus spp. are also well accepted as consumable product. Even further, the berries of Morus spp. naturally contain citric acid which is toxic for unwanted micro-organisms.
The extract of the berries of Morus spp. shows in particular beneficial effects if it is directly co-administered with the food product with the high glycemic index.
The composition of the present invention serves to treat or prevent conditions and/or disorders, for example chronic diseases, linked to foods with a high glycemic index. It avoids the generation of glucose peaks in the bloodstream. As such, the composition of the present invention may be used to at least partially avoid the generation of glucose peaks in
the blood of a consumer after consumption of a meal or beverage rich in digestible carbohydrates.
The meal may be a food rich in digestible carbohydrates, and the beverage may be rich in sucrose and/or maltose. It allows increasing the time span during which a body can use ingested food as energy source. Hence, the composition of the present invention may be used to increase the time span during which energy can be extracted from ingested food.
It also allows prolonging the feeling of satiety after consumption of the composition.
The disorders linked to foods with a high glycemic index that may be treated or prevented by the composition of the present invention may be selected from the group consisting of glucose intolerance abnormalities, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), diabetes, overweightness , obesity, high blood pressure, high blood cholesterol, and heart disease.
"Overweight" is defined for an adult human as having a BMI between 24 and 28 in China or 25 and 30 in western countries.
"Body mass index" or "BMI" means the ratio of weight in kg divided by the height in metres, squared.
"Obesity" is a condition in which the natural energy reserve, stored in the fatty tissue of animals, in particular humans and other mammals, is increased to a point where it is associated with certain health conditions or increased mortality. "Obese" is defined for an adult human as having a BMI greater than 28 in China and 30 in western countries.
The composition may also be used to support weight management.
The composition of the present invention may also consist of an extract of the berries of Morus spp .
The composition of the present invention may be any kind of consumable composition, for example selected from the group consisting of food products, animal food products or pharmaceutical compositions. For example, the composition may be a nutritional composition, a nutraceutical , a drink, a food additive or a medicament.
As such, the composition of the present invention may be intended to be consumed immediately before, during and/or immediately after a meal or beverage.
Immediately before or after a meal shall be understood as the time frame ranging form about 30 minutes before a meal to about 30 minutes after a meal, preferably about 15 minutes before a meal to about 15 minutes after a meal.
If the composition is to be consumed during a meal, it may be intended to be mixed with the meal or it may be consumed as accompanying drink, for example.
Any kind of berries from the Morus spp. may be used for the purposes of the present invention. For example, the Morus spp. may be selected from the group consisting of White Mulberry (Morus alba L.) , Black Mulberry (Morus nigra L.), American Mulberry, Red Mulberry (Morus rubra L.) , hybrid forms between Morus alba and Morus rubra, Korean Mulberry (Morus australis) , Himalayan Mulberry (Morus laevigata) , and combinations thereof
The composition of the present invention may contain any amount of an extract of the berries of Morus spp.. The
effectiveness of the composition follows a dose-response curve which eventually reach a plateau phase at very high concentrations of an extract of the berries of Morus spp ..
For example, the composition of the present invention may comprise at least 10 weight-%, at least 20 weight-%, at least 30 weight-%, at least 40 weight-%, at least 50 weight-%, at least 60 weight-%, at least 70 weight-%, at least 80 weight-%, or at least 90 weight-% of an extract of the berries of Morus spp . The berries of Morus spp. contain for example 1- deoxyno j irimycin (DNJ) in very large quantities compared to other plants and other parts of the Morus plant.
1-deoxyno jirimycin (DNJ) is thought to inhibit intestinal and pancreatic a-glucosidase. In one embodiment of the present invention the composition comprises at least 0.1 mg 1-deoxyno jirimycin (DNJ) per g dry weight, preferably at least 1 mg DNJ per g dry weight.
The berries of Morus ssp. contain also anthocyanins and flavonoids, which both have beneficial effects for the health of the consumer.
Hence, the composition of the present invention may comprise DNJ, anthocyanins and flavonoids in a weight ratio in the range of about 1:0.07:0.05 to 1:45:1.5.
DNJ may act in concert and/or synergistically with other analogues of DNJ present in mulberry.
The present invention also extends to a method to reduce the glycemic index of a food product, e.g. a food product with a
high glycemic index, comprising the step of adding an extract of the berries of Morus spp . to the food product.
Those skilled in the art will understand that they can freely combine all features of the present invention described herein, without departing from the scope of the invention as disclosed. In particular, features described for the composition of the present invention may be applied to the method of the present invention and vice versa.
Further advantages and features of the present invention are apparent from the following Examples and Figures.
Description of Figures
Figure 1 shows the blood glucose response of maltose in mice as affected by mulberry fruit juice (MB) at different dose levels or the positive control acarbose. Data are average of results from 10 mice. Detailed description can be found in Example 1 below.
Figure 2 shows postprandial blood glucose response of white bread as affected by MB in healthy subjects. Detailed description can be found in the Example 2 below. Figure 3 shows the effect of mulberry juice on blood glucose level in Chinese adults.
Mode of Carrying Out the Invention
Example 1 :
The effect of mulberry juice on blood glucose level in animals was assessed as follows:
Experimental D
Male ICR mice age around 5 weeks old and body weight around 24-28 g were purchased from Shanghai Slac Laboratory Animal Co Ltd. They were hosted in a SPF grade animal facility and maintained under 12:12 light-dark cycle with free access to water and food. The regular diet contained 24% protein, 5.4% fat and 59% carbohydrate by weight. Mulberry fruit juice (MB) to be tested was in a concentrated form ( 60 0 Brix) and obtained from the Bosun Healthy Food R&D Center Guangdong, China. It was dissolved in distilled water to the final concentration of 0.1, 0.2 and 0.4 g/ml. Maltose was dissolved in distilled water to a final concentration of 0.25 g/ml. Acarbose was dissolved in distilled water to a final concentration of 2 mg/ml.
The mice were randomized based on the rank of body weight of the experiment day into 5 groups (n=10 in each group) . Three levels of MB (1, 2 and 4 g/kg BW) , plus the negative control (water) and the positive control (acarbose) , were evaluated for their effect on maltose digestion by co-ingestion with maltose solution. The dietary treatment of five groups were as following:
Group 1: Maltose 2.5g/kg + MB lg/kg
Group 2: Maltose 2.5g/kg + MB 2g/kg
Group 3: Maltose 2.5g/kg + MB 4g/kg
Group 4: Maltose 2.5g/kg + Acarbose 20mg/kg
Group 5: Maltose 2.5g/kg + Vehicle (distilled water)
Specifically, after 6 hours fasting, the mice in group 1 to 3 were given 10 ml/kg of maltose (0.25 g/ml) together with 10 ml/kg of different doses of MB (0.1, 0.2 and 0.4 g/ml) by gavage . The mice in group 4 were given 10 ml/kg of maltose
(0.25g/ml) together with 10 ml/kg of acarbose (2mg/ml) by gavage . The mice in group 5 were given 10 ml/kg of maltose
(0.25g/ml) together with 10 ml/kg of vehicle (distilled water) by gavage. Blood glucose values were measured at 0, 30, 60 and 120 min after maltose loading by clipping the tail of the mice using a ACCU-CHEK Glucose Monitor (Roche Diagnostics GmbH, Mannheim, Germany) .
Results :
The results of oral maltose test are shown in Figure 1. High dose of MB (4 g/kg) significantly reduced the postprandial increase of glucose level at 30 minutes after maltose loading, and tendency of decrease was also observed in the medium dose group (3 g/kg (p=0.10) . These data provides strong evidence on alpha-glucosidase inhibitory activity of the mulberry fruit juice and the effective dose is around 4/kg BW in mice.
Example 2 : A crossover clinical study was designed to study the postprandial glycemia after ingestion of mulberry fruit juice (MB) with a high carbohydrate diet (white bread) .
Dietary Treatments:
Control Product: White bread plus 10 g of a sugar solution containing same amount of mono- and di-sugars as in 10 g of MB. And the total digestible carbohydrates are 75 grams.
Test Product: White bread plus 10 g of MB with total of 75 grams of digestible carbohydrates.
White Bread was purchased from Walmart (Zhichun Road Store) in Beijing. Mulberry fruit juice concentrate was 60 0 Brix,
obtained from Bosun Healthy Food R&D Center Guangdong, China. Sugar solution was prepared by Nestle R&D Shanghai based on the results of component analysis of mulberry juice.
Subjects : Twenty-three healthy subjects participated in this study. The age of subjects ranged from 20 to 50 year old, 16 females and 7 males. The average Body Mass Index (BMI) was 21.54 kg/m2, ranging from 18.08 - 24.44.
Experimental Design: In a crossover design, subjects were randomly given either control product or test product after overnight fasting. The washout period was one week. All dietary products were taken orally. All foods were consumed within 12 minutes, 250 ml of water was given with each product. A stopwatch was started for each subject as soon as the subject started eating. Blood samples were collected at time 0, 15, 30, 45, 60, 90, and 120 minutes for postprandial glucose monitoring.
Results :
The mean blood glucose response to the test products is shown in Figure 2. Fasting glucose levels did not differ before the treatments. The maximum peak concentration of glucose was statistically lower in the MB group compared to the Sugar group (p=0.0032) .
The incremental blood glucose AUC was determined by a mixed log-linear trapezoidal model, excluding area that fell below 0 min values. The mixed log-linear trapezoidal model performed the AUC calculation in the following way: the linear rule (trapezoidal) is applied to the range where concentration is
ascending and the log linear rule is applied to the range where concentration is descending. Combination of the two trapezoidal methods enhance the estimation of the AUC in reducing errors inherent to both methods by applying them under condition of best estimate.
The glycemic index was calculated by dividing the area under the curve (AUC) for the Test Product by the AUC for the Control Product. MB was associated with reduction of blood glucose AUC over 120 minutes compared to ingestion of the Control Product. The Mean Glycemic Index of MB versus the control (AUCMB/AUCC) was 80%, which was borderline significant at p=0.0677.
These results provide evidence on the hypoglycemic activity of Mulberry fruit juice concentrate in healthy volunteers when consumed together with a carbohydrate-rich diet. MB is effective in lowering postprandial glycemia. The glycemic index of white bread was reduced by 20% when ingested together with MB.
Example 3 : The effect of mulberry juice on blood glucose level in Chinese adults was assessed.
This clinical trial demonstrates the effect of mulberry juice concentrate on long-lasting energy, especially the Tmax and Cmax of 4-hour postprandial blood glucose after taking the mulberry juice together with a cereal. The primary parameters were the changes in blood glucose level after co-ingesting mulberry juice with a rice-based cereal with a high carbohydrate content as comparing to the cereal alone.
The clinical trial also allows showing the effect of mulberry juice on the time it takes the blood glucose level to return to baseline level.
Further, the effect of mulberry juice concentrate on AUC of postprandial glycemia during 4 hours after taking the mulberry juice together with a cereal is demonstrated.
The effect of mulberry juice concentrate on insulinemia (Cmax, Tmax, AUC) during 4 hours after taking the mulberry juice together with a cereal is shown The effect of mulberry juice concentrate on satiety over 4 hours after food intake is shown including Tmax and Cmax.
110 healthy voluntary Chinese people (50% males and 50% females), age 18-50, were recruited for a trial.
The subjects were tested on two dietary treatments in a random order, while the washout period was 1 week.
Treatment 1: Rice-based cereal flakes plus sugar solution containing same amount of mono- and di-sugars as in mulberry fruit juice concentrate.
Treatment 2 : Rice-based cereal flakes plus mulberry fruit juice concentrate.
Mulberry fruit juice concentrate, Brix 60 (approx. 60% sugar), was obtained from Bosun Healthy Food R&D Center of Guangdong, China . lOg of Mulberry fruit juice concentrate or lOg of sugar solution were consumed together with the cereal. Total food
portion (cereal with sugar solution or cereal with mulberry fruit juice) contained 75 g digestible carbohydrates.
The study was carried out at the Shanghai Sixth People's Hospital, Shanghai Jiaotong University. This hospital is specialized in treating diabetic patients.
For subjects participating the trial, the experimental period was 8±1 days. On Day 1, each subject received one of the two treatments in a random manner after an overnight fast, and consumed the treatment within 12 minutes. Venous blood samples were drawn immediately before eating and at 15, 30, 45, 60, 90, 120, 150, 180, 210, and 240 min after eating has commenced. On Day 8±1, each subject received another one of the two treatments in an identical fashion, venous blood samples were drawn in an identical fashion. The total duration for each subject was around two weeks.
The results of this study are shown in the following tables 1- 5 and in figure 3.
Table 1 Postprandial satiety score ( x ± s )
Time ( min) CONTRL MULBERRY P VALUE ( aired t-test)
( n=107) ( n=107)
0 29.37*14.01 30.25i13.96 0.563
15 52.93i24.48 53.89i17.71 0.609
30 52.61i18.02 53.76i18.87 0.403
60 51.07i18.06 52.35i16.73 0.288
120 46.05i17.34 44.74*16.70 0.392
180 36.96±15.14 37.28i15.20 0.822
240 24.15*14.92 24.44i14.92 0.832
Table 2 AUC of blood glucose postprandial (mmol/L*mins) (
CONTRL MULBERRY P Value
( n=107) (n=107) (paired t-test)
2riAUC 698.72*120.79 711.05*118 31 0.211
4 AUC 1246.78*176.24 1243.58*172.02 0.845
2-4 difference of AUC 533.29*76.69 542.98*91.58 0.346
AUC of blood insulin postprandial (mmol L *mins) { x - s )
CONTRL MULBERRY P Value
(n=104) ( n=104) (paired t-test)
2hAUC 4994.90*2306.67 4551.14*1950.62 0.030
4ft AUC 7241 11*3466.41 6487.41*2851.94 0.018
2-4h difference of AUC 2272.60*1583.50 1917.83*1200.33 0.031
Table 4 Postprandial blood glucose Tmax, Insulin Tmax and the peak value ( x ± s )
CONTRL MULBERRY P Value
( n=107) ( n=107) (paired t-test)
Blood glucose Tmax 38.41*10.34 41.36*23.02 0.231
(mins)
Peak blood glucose 7.58*1.27 7.34*1.20 0.019
(mmol L)
Insulin Tmax 76.73*37.62 63.82*25.53 0
(mins)
Peak insulin 49.90*23.87 55.24*32.60 0.186
(mmol/L)
Table 5 Blood glucose levels (mmol/L) ( x ± s ) mean±SD d-value meaniSD
CONTRL MULBERRY CONTRL MULBERRY
0 4.73*0.40 4.76*0.46
15 5.41 ±0.75 5.40±0.58 0.69±0.68 0.64±0.53
30 7.15±1.01 6.91 ±1 .11 2.43±0.92* 2.15±1.01
45 7.10±1.49 6.81 ±1 .49 2.38±1.38 2.04±1.41
60 6.28±1.57 6.14±1 .66 1.56±1.49 1.38±1.59
90 5.45±1.28 5.40±1 .33 0.73±1.25 0.64±1.26
120 5.06±1.08 5.08±1 .05 0.33±1.05 0.32±1.05
150 4.86±0.91 4.89±0.90 0.14±0.94 0.13±0.91
180 4.22±0.79* 4.50±0.98 -0.50±0.82Δ -0.26±0.98
210 4.05±0.72* 4.24±0.69 -0.68±0.73 -0.52±0.75
240 4.18±0.59 4.22±0.44 -0.55±0.57 -0.54±0.54
*P<0.05, comparing with control group
ΔΡ=0.05, comparing with control group
These results confirm the hypoglycemic activity of Mulberry fruit juice concentrate in healthy volunteers when consumed together with a carbohydrate-rich diet. Evidence is provided that a glucose peak is reduced, while glucose is available in the blood for extended times, in particular 2 - 4 hours after ingestion .
Claims
1. Composition comprising an extract of the berries of Morus spp . for use in the treatment or prevention of conditions linked to foods with a high glycemic index.
2. Composition in accordance with claim 1, wherein the conditions linked to foods with a high glycemic index are selected from the group consisting of glucose intolerance abnormalities, impaired glucose tolerance (IGT) , impaired fasting glucose (IFG), diabetes, overweight, obesity, metabolic syndrome, high blood pressure, high blood cholesterol, and heart disease.
3. Composition in accordance with one of the preceding claims to support weight management.
4. Composition in accordance with one of the preceding claims for increasing the time span during which energy can be extracted from ingested food.
5. Composition in accordance with one of the preceding claims for at least partially avoiding the generation of glucose peaks and/or insulin peaks in the blood of a consumer after consumption of a meal or beverage rich in digestible carbohydrates.
6. Composition in accordance with one of the preceding claims to be consumed immediately before, during and/or immediately after a meal or beverage.
7. Composition in accordance with one of the preceding claims consisting of an extract of the berries of Morus spp .
8. Composition in accordance with one of the preceding claims, wherein the Morus spp . are selected from the group consisting of White Mulberry (Morus alba L.)r Black Mulberry (Morus nigra L.), American Mulberry, Red Mulberry (Morus rubra L.) , hybrid forms between Morus alba and Morus rubra, Korean Mulberry (Morus australis) , Himalayan Mulberry (Morus laevigata) , and combinations thereof .
9. Composition in accordance with one of the preceding claims, wherein the composition further comprises a carbohydrate source.
10. Composition in accordance with one of the preceding claims, wherein the carbohydrate source represents at least 50 %, preferably at least 65 %, more preferred at least 80 % of the energy of the composition.
11. Composition in accordance with one of the preceding claims, wherein the composition has an energy density in the range of about 0.2 kcal/g to _5 kcal/g.
12. Composition in accordance with one of the preceding claims, wherein the composition comprises at least 50 weight-% of an extract of the berries of Morus spp.
13. Composition in accordance with one of the preceding claims, wherein the composition comprises at least 0.1 mg/g 1-deoxyno jirimycin (DNJ) , preferably at least 1 mg/g DNJ.
14. Composition in accordance with one of the preceding claims comprising DNJ, anthocyanins and flavonoids in a weight ratio in the range of about 1:0.07:0.05 to 1:45:1.5.
15. Method to reduce the glycemic index of a food product comprising the step of adding an extract of the berries of Morus spp.to the food product.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2011/083299 WO2013078658A1 (en) | 2011-12-01 | 2011-12-01 | Morus berries and avoiding glucose peaks |
CN201180075610.2A CN103998051A (en) | 2011-12-01 | 2011-12-01 | Morus berries and avoiding glucose peaks |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2011/083299 WO2013078658A1 (en) | 2011-12-01 | 2011-12-01 | Morus berries and avoiding glucose peaks |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013078658A1 true WO2013078658A1 (en) | 2013-06-06 |
Family
ID=48534636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2011/083299 WO2013078658A1 (en) | 2011-12-01 | 2011-12-01 | Morus berries and avoiding glucose peaks |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN103998051A (en) |
WO (1) | WO2013078658A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015159195A1 (en) * | 2014-04-13 | 2015-10-22 | Marmar Investment Sp. Z O.O. | Dietary compositions for reducing blood glucose levels and for weight management |
WO2016005425A1 (en) * | 2014-07-10 | 2016-01-14 | Egb Epigeneticbalance Ag | Method for evaluating foods, and nutritional system for the prevention and treatment of chronic diseases |
WO2017220423A1 (en) * | 2016-06-21 | 2017-12-28 | Unilever N.V. | Savoury concentrate comprising mulberry fruit material |
WO2019068453A1 (en) * | 2017-10-03 | 2019-04-11 | Unilever N.V. | A food concentrate for preparing a sauce, soup, condiment or gravy |
IT201900023997A1 (en) * | 2019-12-13 | 2021-06-13 | Mario Paolo Donnaloja | FOOD SUPPLEMENT FOR THE REGULATION OF METABOLISM |
WO2021214292A1 (en) | 2020-04-24 | 2021-10-28 | Société des Produits Nestlé S.A. | Composition comprising fibre and mulberry |
WO2021214326A1 (en) | 2020-04-24 | 2021-10-28 | Société des Produits Nestlé S.A. | Use of mulberry extract for controlling postprandial glucose response |
US11278037B2 (en) | 2017-09-22 | 2022-03-22 | Conopco Inc. | Composition comprising vegetable oil and apple cider vinegar |
WO2023165856A1 (en) | 2022-03-02 | 2023-09-07 | Société des Produits Nestlé S.A. | Use of a composition for managing postprandial glucose response and associated disorders |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021086271A1 (en) * | 2019-10-31 | 2021-05-06 | Mark One Innovation Center Company Limited | A composition containing mulberry extract and production method thereof |
CN113040377A (en) * | 2021-03-29 | 2021-06-29 | 广东省农业科学院蚕业与农产品加工研究所 | Purple sweet potato nutritional meal replacement powder and preparation process thereof |
CN113461532B (en) * | 2021-07-05 | 2023-05-02 | 南昌大学 | Black Sang Su A with blood sugar reducing effect and preparation method and application thereof |
CN113480503B (en) * | 2021-07-05 | 2023-01-03 | 南昌大学 | Black mulberry element B with blood sugar reducing effect and preparation method and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101926853A (en) * | 2009-06-25 | 2010-12-29 | 浙江京新药业股份有限公司 | Medicine composition with function of lowering blood sugar level as well as preparation method and application thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009178099A (en) * | 2008-01-31 | 2009-08-13 | Iwate Univ | Malt alcoholic beverage and method for producing the same |
-
2011
- 2011-12-01 WO PCT/CN2011/083299 patent/WO2013078658A1/en active Application Filing
- 2011-12-01 CN CN201180075610.2A patent/CN103998051A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101926853A (en) * | 2009-06-25 | 2010-12-29 | 浙江京新药业股份有限公司 | Medicine composition with function of lowering blood sugar level as well as preparation method and application thereof |
Non-Patent Citations (2)
Title |
---|
CHEN CHENG ET AL.: "The research development of the active materials of Chinese medicin mulberry", JOURNAL OF CHINESE MEDICINAL MATERIALS, vol. 33, no. 10, 31 October 2010 (2010-10-31), pages 1660 - 1662 * |
WANG CHUYAN ET AL.: "The research and development of mulberry food", THE FOOD INDUSTRY, 31 March 2011 (2011-03-31), pages 95 - 97 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015248506B2 (en) * | 2014-04-13 | 2020-09-03 | Marmar Investment Sp. Z O.O. | Dietary compositions for reducing blood glucose levels and for weight management |
CN106456692A (en) * | 2014-04-13 | 2017-02-22 | 马尔玛投资有限公司 | Dietary compositions for reducing blood glucose levels and for weight management |
WO2015159195A1 (en) * | 2014-04-13 | 2015-10-22 | Marmar Investment Sp. Z O.O. | Dietary compositions for reducing blood glucose levels and for weight management |
US11071767B2 (en) | 2014-04-13 | 2021-07-27 | Marmar Investment Sp. Z O.O. | Dietary compositions for reducing blood glucose levels and for weight management |
WO2016005425A1 (en) * | 2014-07-10 | 2016-01-14 | Egb Epigeneticbalance Ag | Method for evaluating foods, and nutritional system for the prevention and treatment of chronic diseases |
WO2017220423A1 (en) * | 2016-06-21 | 2017-12-28 | Unilever N.V. | Savoury concentrate comprising mulberry fruit material |
CN109640699A (en) * | 2016-06-21 | 2019-04-16 | 荷兰联合利华有限公司 | Salty fresh concentrate comprising mulberry tree fruit material |
US11278037B2 (en) | 2017-09-22 | 2022-03-22 | Conopco Inc. | Composition comprising vegetable oil and apple cider vinegar |
WO2019068453A1 (en) * | 2017-10-03 | 2019-04-11 | Unilever N.V. | A food concentrate for preparing a sauce, soup, condiment or gravy |
IT201900023997A1 (en) * | 2019-12-13 | 2021-06-13 | Mario Paolo Donnaloja | FOOD SUPPLEMENT FOR THE REGULATION OF METABOLISM |
WO2021214292A1 (en) | 2020-04-24 | 2021-10-28 | Société des Produits Nestlé S.A. | Composition comprising fibre and mulberry |
WO2021214326A1 (en) | 2020-04-24 | 2021-10-28 | Société des Produits Nestlé S.A. | Use of mulberry extract for controlling postprandial glucose response |
WO2023165856A1 (en) | 2022-03-02 | 2023-09-07 | Société des Produits Nestlé S.A. | Use of a composition for managing postprandial glucose response and associated disorders |
Also Published As
Publication number | Publication date |
---|---|
CN103998051A (en) | 2014-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013078658A1 (en) | Morus berries and avoiding glucose peaks | |
RU2356247C2 (en) | Combinations and compositions containing fatty acids and amino acids, their application for prevention and delay of progressing or treatment of diabetes and diabetes associated diseases and conditions, method of weight reduction in mammal, kit | |
EP2203070B1 (en) | Pomegranate extracts, nutritional products containing them and their uses | |
EP2100604B1 (en) | Medium chain dicarboxylic acids and their derivates and metabolic disorders | |
Choudhary et al. | Development of functional food products in relation to obesity | |
US20030064937A1 (en) | Composition for reducing appetite in mammals | |
WO2008076579A2 (en) | Method of controlling body weight in estrogen-insufficient women | |
US8722614B2 (en) | Adiponectin production enhancer | |
WO2013148685A1 (en) | Pea protein containing nutritional compositions | |
EP4356961A2 (en) | Use of whey protein micelles for controlling postprandial glucose response | |
CA2844823A1 (en) | Method of transforming a meal | |
WO2005082390A1 (en) | Fat accumulation inhibitors | |
KR20060024766A (en) | Food for improving clinical conditions capable of lowering the concentration of low-molecular weight nitrogen-containing compounds in blood | |
KR102239066B1 (en) | Composition for preventing, ameliorating or treating metabolic diseases comprising mixture of plant extract as effective component | |
WO2014016265A1 (en) | Hawthorn and phytosterols and their effect on metabolic disorders | |
WO2023127961A1 (en) | Gaba-containing composition | |
WO2010132774A1 (en) | L-arabinose plus chromium for controlling the metabolization of sucrose | |
CN102204671A (en) | Composition containing morus berry | |
WO1998008527A1 (en) | Yacon/oolong blend tea | |
Amagase | A combination of various functional food ingredients as a weight management program: randomized, placebo-controlled, and double-blind human clinical studies | |
CN113100443A (en) | Composition and soft capsule for relieving gout and preparation method thereof | |
KR20200045036A (en) | Composition for preventing, ameliorating or treating metabolic diseases comprising mixture of plant extract as effective component | |
Ahmad et al. | Metabolic disorders | |
Gifford-Jones | No nonsense weight management. | |
Sivapriya et al. | CINNAMON: POTENTIAL ROLE IN THE PREVENTION OF TYPE 2 DIABETES MELLITUS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11876803 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11876803 Country of ref document: EP Kind code of ref document: A1 |